KYTX · Kyverna Therapeutics, Inc.
$8.13
-0.74 (-8.34%)
At close · Aug 20
Market Cap
$548.55M
Shares
61.84M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$8.13
Open$8.73
Day$8.11–8.76
52W close$3.43–11.25
Avg vol 30d941K
Short int8.2M · 13.2% float · 8.7d
Short vol56%
Last earningsMay 12, 2026
DataFeb 2024–Aug 2026
Filing10-Q · Aug 11
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 11, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Buy
Momentum
Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−3%
below
Price vs 50-day avg
+0%
above
RSI (14)
51
neutral
MACD trend
Positive
52-week position
60%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+12%
trailing
6-month return
−1%
trailing
YTD return
−14%
this year
Relative strength
−12%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $8 › 200d $8 — 200d above 50d
Institutional flow
Accumulating
+6% holders QoQ · +30 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
13.22% of float · ▲ +4.2% MoM · 8.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
119 holders — near 2-yr high, broad support
Squeeze score
67
elevated · 0–100
Fundamentals
EPS growth
−9%
Y/Y
Free cash flow
$-153.7M
Balance sheet
$99.4M
net cash
Quant / Vol
risk profile
Volatility
101%
annualized · 1-yr
Max drawdown
−37%
past year
ATR
6.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−3%
Neutral
Price vs 50-day avg
+0%
Bullish
RSI (14)
51
Neutral
MACD trend
Positive
Bullish
52-week position
60%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $8 › 200d $8 — 200d above 50d
Institutional flow
Accumulating
+6% holders QoQ · +30 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
13.22% of float · ▲ +4.2% MoM · 8.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
119 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $3
Now $8 · 60%
Range high $11
vs 200-day avg -3%
vs 50-day avg +0%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KYTX
this stock
Kyverna Therapeutics, Inc.
|
$548.55M | -13.5% | — | — | 13.2% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KYTX | +0.6% | +11.5% | -1.0% | +11.4% | -13.5% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +2.6% | +8.2% | -12.1% | +9.3% | -25.3% |
Key facts
CIK
1994702
CUSIP
501976104
13F (30d)
118 filings
117 filers
Visit website
Investor relations